Discovery of novel benzofuro[3,2-b]quinoline derivatives as dual CDK2/Topo I inhibitors.

[1]  Yingshi Zhang,et al.  DHW-221, a Dual PI3K/mTOR Inhibitor, Overcomes Multidrug Resistance by Targeting P-Glycoprotein (P-gp/ABCB1) and Akt-Mediated FOXO3a Nuclear Translocation in Non-small Cell Lung Cancer , 2022, Frontiers in Oncology.

[2]  Chang Xu,et al.  ZDQ-0620, a Novel Phosphatidylinositol 3-Kinase Inhibitor, Inhibits Colorectal Carcinoma Cell Proliferation and Suppresses Angiogenesis by Attenuating PI3K/AKT/mTOR Pathway , 2022, Frontiers in Oncology.

[3]  H. Ding,et al.  Design, synthesis, and biological evaluation of β-carboline 1,3,4-oxadiazole based hybrids as HDAC inhibitors with potential antitumor effects. , 2022, Bioorganic & medicinal chemistry letters.

[4]  H. Ding,et al.  Facile synthesis of C1-substituted β-carbolines as CDK4 inhibitors for the treatment of cancer. , 2022, Bioorganic chemistry.

[5]  Nan Wang,et al.  Discovery of novel β-carboline derivatives as selective AChE inhibitors with GSK-3β inhibitory property for the treatment of Alzheimer's disease , 2021, European Journal of Medicinal Chemistry.

[6]  A. Ferguson,et al.  Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement. , 2021, Journal of medicinal chemistry.

[7]  S. Bharate,et al.  Role of basic aminoalkyl chains in the lead optimization of Indoloquinoline alkaloids. , 2021, European journal of medicinal chemistry.

[8]  J. Lapek,et al.  Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer. , 2021, Journal of medicinal chemistry.

[9]  Qingchun Zhao,et al.  Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease. , 2021, European journal of medicinal chemistry.

[10]  Ying-Qian Liu,et al.  Design, Synthesis, and Antifungal Evaluation of Cryptolepine Derivatives against Phytopathogenic Fungi. , 2021, Journal of agricultural and food chemistry.

[11]  C. Masdeu,et al.  A patent review of topoisomerase I inhibitors (2016–present) , 2021, Expert opinion on therapeutic patents.

[12]  James Lin,et al.  Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2. , 2020, Journal of medicinal chemistry.

[13]  S. Pal,et al.  Development of a metabolically stable topoisomerase I poison as anticancer agent. , 2020, European journal of medicinal chemistry.

[14]  David J Newman,et al.  Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. , 2020, Journal of natural products.

[15]  W. Tilley,et al.  Targeting CDK2 in cancer: challenges and opportunities for therapy. , 2019, Drug discovery today.

[16]  Qingchun Zhao,et al.  Novel ADAM-17 inhibitor ZLDI-8 inhibits the proliferation and metastasis of chemo-resistant non-small-cell lung cancer by reversing Notch and epithelial mesenchymal transition in vitro and in vivo. , 2019, Pharmacological research.

[17]  Yingying Guo,et al.  To control or to be controlled? Dual roles of CDK2 in DNA damage and DNA damage response. , 2019, DNA repair.

[18]  A. Eastman,et al.  Differential Sensitivity to CDK2 Inhibition Discriminates the Molecular Mechanisms of CHK1 Inhibitors as Monotherapy or in Combination with the Topoisomerase I Inhibitor SN38. , 2019, ACS pharmacology & translational science.

[19]  W. Tilley,et al.  Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update. , 2018, Journal of medicinal chemistry.

[20]  Jane A. Endicott,et al.  Structural insights into the functional diversity of the CDK–cyclin family , 2018, Open Biology.

[21]  Zhishu Huang,et al.  Design, Synthesis, and Evaluation of Novel p-(Methylthio)styryl Substituted Quindoline Derivatives as Neuroblastoma RAS (NRAS) Repressors via Specific Stabilizing the RNA G-Quadruplex. , 2018, Journal of medicinal chemistry.

[22]  G. Chillemi,et al.  Type I DNA Topoisomerases. , 2017, Journal of medicinal chemistry.

[23]  Rangappa S. Keri,et al.  New Tacrine Hybrids with Natural‐Based Cysteine Derivatives as Multitargeted Drugs for Potential Treatment of Alzheimer's Disease , 2016, Chemical biology & drug design.

[24]  S. Apers,et al.  The value of central-African traditional medicine for lead finding: Some case studies. , 2015, Journal of ethnopharmacology.

[25]  Zhishu Huang,et al.  Targeting G-quadruplex nucleic acids with heterocyclic alkaloids and their derivatives. , 2015, European journal of medicinal chemistry.

[26]  Agnieszka K. Witkiewicz,et al.  The history and future of targeting cyclin-dependent kinases in cancer therapy , 2015, Nature Reviews Drug Discovery.

[27]  D. Paterson,et al.  8-Substituted O(6)-cyclohexylmethylguanine CDK2 inhibitors: using structure-based inhibitor design to optimize an alternative binding mode. , 2014, Journal of medicinal chemistry.

[28]  A. Schnittger,et al.  Cell cycle control across the eukaryotic kingdom. , 2013, Trends in cell biology.

[29]  L. Hurley,et al.  Anticancer activity and cellular repression of c-MYC by the G-quadruplex-stabilizing 11-piperazinylquindoline is not dependent on direct targeting of the G-quadruplex in the c-MYC promoter. , 2012, Journal of medicinal chemistry.

[30]  J. Gut,et al.  Incorporation of basic side chains into cryptolepine scaffold: structure-antimalarial activity relationships and mechanistic studies. , 2011, Journal of medicinal chemistry.

[31]  D. J. Price,et al.  Synthesis and evaluation of pyrazolo[1,5-b]pyridazines as selective cyclin dependent kinase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[32]  W. Lu,et al.  Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins , 2008, Molecular Cancer Therapeutics.

[33]  Lin Ma,et al.  Synthesis and evaluation of quindoline derivatives as G-quadruplex inducing and stabilizing ligands and potential inhibitors of telomerase. , 2005, Journal of medicinal chemistry.

[34]  S. Croft,et al.  Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action. , 2005, Journal of medicinal chemistry.

[35]  N. Gooderham,et al.  In vitro genotoxicity of the West African anti-malarial herbal Cryptolepis sanguinolenta and its major alkaloid cryptolepine. , 2005, Toxicology.

[36]  Anna Vulpetti,et al.  3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding. , 2004, Journal of medicinal chemistry.

[37]  A. J. Kaye,et al.  Synthesis and cytotoxic activity of N-(2-diethylamino)ethylcarboxamide and other derivatives of 10H-quindoline. , 2002, Bioorganic & medicinal chemistry.

[38]  David J. Chen,et al.  Ku affects the ataxia and Rad 3-related/CHK1-dependent S phase checkpoint response after camptothecin treatment. , 2002, Cancer research.

[39]  D. Kingston,et al.  Synthesis and biological evaluation of analogues of cryptolepine, an alkaloid isolated from the Suriname rainforest. , 1999, Journal of natural products.

[40]  L. Angenot,et al.  The DNA intercalating alkaloid cryptolepine interferes with topoisomerase II and inhibits primarily DNA synthesis in B16 melanoma cells. , 1998, Biochemistry.